A recent study suggests that people who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise plans.
Published data in a leading medical journal demonstrates that while obese people often shed a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users using such medications must be cognizant of the potential of quick rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
That rate of regain means a return to starting weight in about a year and a half.
Weighing Treatments
The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
Scientists emphasize that individuals who lose weight through diet and exercise usually see a slower weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Quick Regain
Nutrition scientists believe the mode of action of the jabs accounts for the accelerated weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating much more probable."
A Chronic Condition?
Health authorities recommend the injections for people with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, given the likelihood of relapse, the treatment might need to be long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "underscore the chronic nature of obesity," akin to managing diseases like diabetes.
User Testimonies
Users who have stopped the jabs report a powerful return of appetite.
"It was like something activating and you're instantly ravenous," recalled an individual.
This challenge is exacerbated if individuals have not established lasting lifestyle or habit modifications during therapy.
Significant Use
Recent estimates show that millions of people in the UK have tried weight-loss jabs in the past year, with demand continuing to grow.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are potent tools for weight loss, they are not a magic solution and maintained weight loss relies on integrated lifestyle support.
